Early-stage Alzheimer disease: getting trial-ready

Slowing the progression of Alzheimer disease (AD) might be the greatest unmet medical need of our time. Although one AD therapeutic has received a controversial accelerated approval from the FDA, more effective and accessible therapies are urgently needed. Consensus is growing that for meaningful di...

Descripción completa

Detalles Bibliográficos
Autores principales: Aisen, Paul S., Jimenez-Maggiora, Gustavo A., Rafii, Michael S., Walter, Sarah, Raman, Rema
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8978175/
https://www.ncbi.nlm.nih.gov/pubmed/35379951
http://dx.doi.org/10.1038/s41582-022-00645-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8978175/
https://www.ncbi.nlm.nih.gov/pubmed/35379951
http://dx.doi.org/10.1038/s41582-022-00645-6

Ejemplares similares